306 related articles for article (PubMed ID: 33652960)
1. Novel Targeted Therapies for Advanced Cholangiocarcinoma.
Rizzo A; Brandi G
Medicina (Kaunas); 2021 Feb; 57(3):. PubMed ID: 33652960
[TBL] [Abstract][Full Text] [Related]
2. Cholangiocarcinoma miscoding in hepatobiliary centres.
Selvadurai S; Mann K; Mithra S; Bridgewater J; Malik H; Khan SA
Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):635-639. PubMed ID: 33032867
[TBL] [Abstract][Full Text] [Related]
3. Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?
Ricci AD; Rizzo A
Medicina (Kaunas); 2021 Nov; 57(12):. PubMed ID: 34946246
[TBL] [Abstract][Full Text] [Related]
4. The Hallmarks of Liver Fluke Related Cholangiocarcinoma: Insight into Drug Target Possibility.
Loilome W; Namwat N; Jusakul A; Techasen A; Klanrit P; Phetcharaburanin J; Wangwiwatsin A
Recent Results Cancer Res; 2023; 219():53-90. PubMed ID: 37660331
[TBL] [Abstract][Full Text] [Related]
5. Clinical presentation, diagnosis and staging of cholangiocarcinoma.
Forner A; Vidili G; Rengo M; Bujanda L; Ponz-Sarvisé M; Lamarca A
Liver Int; 2019 May; 39 Suppl 1():98-107. PubMed ID: 30831002
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.
Clements O; Eliahoo J; Kim JU; Taylor-Robinson SD; Khan SA
J Hepatol; 2020 Jan; 72(1):95-103. PubMed ID: 31536748
[TBL] [Abstract][Full Text] [Related]
7. Cholangiocarcinoma in Germany: Epidemiologic trends and impact of misclassification.
Walter D; Ferstl P; Waidmann O; Trojan J; Hartmann S; Schnitzbauer AA; Zeuzem S; Kraywinkel K
Liver Int; 2019 Feb; 39(2):316-323. PubMed ID: 30176117
[TBL] [Abstract][Full Text] [Related]
8. Emerging molecular therapeutic targets for cholangiocarcinoma.
Ilyas SI; Gores GJ
J Hepatol; 2017 Sep; 67(3):632-644. PubMed ID: 28389139
[TBL] [Abstract][Full Text] [Related]
9. [Cholangiocarcinoma-diagnosis, classification, and molecular alterations].
Goeppert B
Pathologe; 2020 Sep; 41(5):488-494. PubMed ID: 32757029
[TBL] [Abstract][Full Text] [Related]
10. Tumour stage and overall survival in patients with intrahepatic cholangiocarcinoma and primary sclerosing cholangitis - a retrospective cohort study.
Schramm C; Sapuk A; Hoyer D; Radünz S; Schmidt H
Z Gastroenterol; 2024 Jan; 62(1):37-42. PubMed ID: 38195106
[TBL] [Abstract][Full Text] [Related]
11. Clinical treatment of cholangiocarcinoma: an updated comprehensive review.
Elvevi A; Laffusa A; Scaravaglio M; Rossi RE; Longarini R; Stagno AM; Cristoferi L; Ciaccio A; Cortinovis DL; Invernizzi P; Massironi S
Ann Hepatol; 2022; 27(5):100737. PubMed ID: 35809836
[TBL] [Abstract][Full Text] [Related]
12. Dual-Specificity Phosphatase 11 Is a Prognostic Biomarker of Intrahepatic Cholangiocarcinoma.
Xu L; Wang P; Zhang W; Li W; Liu T; Che X
Front Oncol; 2021; 11():757498. PubMed ID: 34660327
[TBL] [Abstract][Full Text] [Related]
13. Pathologic classification of cholangiocarcinoma: New concepts.
Nakanuma Y; Kakuda Y
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):277-93. PubMed ID: 25966428
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Chemotherapy for Intrahepatic, Perihilar, and Distal Cholangiocarcinoma: a National Population-Based Comparative Cohort Study.
Parente A; Kamarajah SK; Baia M; Tirotta F; Manzia TM; Hilal MA; Pawlik TM; White SA; Dahdaleh FS
J Gastrointest Surg; 2023 Apr; 27(4):741-749. PubMed ID: 36749556
[TBL] [Abstract][Full Text] [Related]
15. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.
Massironi S; Pilla L; Elvevi A; Longarini R; Rossi RE; Bidoli P; Invernizzi P
Cells; 2020 Mar; 9(3):. PubMed ID: 32168869
[TBL] [Abstract][Full Text] [Related]
16. Practical considerations in screening for genetic alterations in cholangiocarcinoma.
Bekaii-Saab TS; Bridgewater J; Normanno N
Ann Oncol; 2021 Sep; 32(9):1111-1126. PubMed ID: 33932504
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review.
Rizzo A; Brandi G
Cancer Treat Res Commun; 2021; 27():100354. PubMed ID: 33756174
[TBL] [Abstract][Full Text] [Related]
18. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
Rizzo A; Ricci AD; Brandi G
Cancer Treat Res Commun; 2021; 27():100356. PubMed ID: 33799004
[TBL] [Abstract][Full Text] [Related]
19. The Smad4-MYO18A-PP1A complex regulates β-catenin phosphorylation and pemigatinib resistance by inhibiting PAK1 in cholangiocarcinoma.
Liu J; Ren G; Li K; Liu Z; Wang Y; Chen T; Mu W; Yang X; Li X; Shi A; Zhao W; Xu B; Chang J; Guo S; Pan C; Zhou T; Zhang Z; Xu Y
Cell Death Differ; 2022 Apr; 29(4):818-831. PubMed ID: 34799729
[TBL] [Abstract][Full Text] [Related]
20. Aldehyde dehydrogenase 3B2 promotes the proliferation and invasion of cholangiocarcinoma by increasing Integrin Beta 1 expression.
Wang Y; Li K; Zhao W; Liu Z; Liu J; Shi A; Chen T; Mu W; Xu Y; Pan C; Zhang Z
Cell Death Dis; 2021 Dec; 12(12):1158. PubMed ID: 34907179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
